CYP2C19 poor metabolizer is associated with clinical outcome of clopidogrel therapy in acute myocardial infarction but not stable angina

Circulation: Cardiovascular Genetics

Volumn 6, Issue 5, 2013, Pages 514-521

  Kim, Ho Sook ^a,b   Chang, Kiyuk ^c   Koh, Yoon Seok ^d   Park, Mahn Won ^e   Choi, Yun Seok ^f   Park, Chul Soo ^f   Oh, Minkyung ^a   Kim, Eun Young ^a,b   Shon, Ji Hong ^a,b   Shin, Jae Gook ^a,b   Seung, Ki Bae ^c  

^a Inje University College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d Uijeongbu St Mary's Hospital   (South Korea)

^e Daejeon St Mary's Hospital   (South Korea)

^f The Catholic University of Korea   (South Korea)

Author keywords

Acute myocardial infarction; Angina; Clopidogrel; CYP2C19 protein; Human; Pharmacogenetics; Stable

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C19;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CYP2C19 GENE; DRUG EFFECT; DRUG METABOLISM; FEMALE; GENE; GENE DOSAGE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; STENT THROMBOSIS; THROMBOCYTE FUNCTION; TREATMENT OUTCOME;

ACUTE MYOCARDIAL INFARCTION; ANGINA, STABLE; CLOPIDOGREL; CYP2C19 PROTEIN, HUMAN; PHARMACOGENETICS;

ADULT; AGED; ALLELES; ANGINA, STABLE; ARYL HYDROCARBON HYDROXYLASES; FEMALE; GENOTYPE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84892399678     PISSN: 1942325X     EISSN: 19423268     Source Type: Journal    
DOI: 10.1161/CIRCGENETICS.113.000109     Document Type: Article

References (34)

1. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KK, et al Stent Anticoagulation Restenosis Study Investigators. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med. 1998;339:1665-1671.
2. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107:2908-2913.
3. Sabatine MS, Cannon CP, Gibson CM, López-Sendón JL, Montalescot G, Theroux P, et al CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med. 2005;352:1179-1189.
4. Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid NA, Okazaki O, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos. 2010;38:92-99.
5. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354-362.
6. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010;304:1821-1830.
7. Paré G, Mehta SR, Yusuf S, Anand SS, Connolly SJ, Hirsh J, et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N Engl J Med. 2010;363:1704-1714.
8. Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or baremetal stents. J Am Coll Cardiol. 2008;51:1925-1934.
9. Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N Engl J Med. 1986;315:983-989.
10. Lee SS, Lee SJ, Gwak J, Jung HJ, Thi-Le H, Song IS, et al. Comparisons of CYP2C19 genetic polymorphisms between Korean and Vietnamese populations. Ther Drug Monit. 2007;29:455-459.
11. Li XQ, Andersson TB, Ahlstrom M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome p450 activities. Drug Metab Dispos. 2004;32:821-827.
12. Hosmer DW Jr, Lemeshow S, May S. Applied Survival Analysis: Regression Modeling of Time to Event Data. Hoboken, NJ: Wiley-Interscience; 2008.
13. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, et al; French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009;360:363-375.
14. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009;373:309-317.
15. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators: effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494-502.
16. Nakazawa G, Finn AV, Joner M, Ladich E, Kutys R, Mont EK, et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation. 2008;118:1138-1145.
17. Goldstein JA, Ishizaki T, Chiba K, de Morais SM, Bell D, Krahn PM, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics. 1997;7:59-64.
18. Ueshima H, Sekikawa A, Miura K, Turin TC, Takashima N, Kita Y, et al. Cardiovascular disease and risk factors in Asia: a selected review. Circulation. 2008;118:2702-2709.
19. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation. 2001;104:2855-2864.
20. Yusuf S, Reddy S, Ounpuu S, Anand S. Global burden of cardiovascular diseases: Part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104:2746-2753.
21. Ahn SG, Lee SH, Yoon JH, Kim WT, Lee JW, Youn YJ, et al. Different prognostic significance of high on-treatment platelet reactivity as assessed by the VerifyNow P2Y12 assay after coronary stenting in patients with and without acute myocardial infarction. JACC Cardiovasc Interv. 2012;5:259-267.
22. Park KW, Park JJ, Jeon KH, Kang SH, Oh IY, Yang HM, et al. Clinical predictors of high posttreatment platelet reactivity to clopidogrel in Koreans. Cardiovasc Ther. 2012;30:5-11.
23. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, et al Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol. 2010;56:919-933.
24. Ma C. Current antithrombotic treatment in East Asia: some perspectives on anticoagulation and antiplatelet therapy. Thromb Haemost. 2012;107: 1014-1018.
25. Gladding P, Webster M, Zeng I, Farrell H, Stewart J, Ruygrok P, et al. The antiplatelet effect of higher loading and maintenance dose regimens of clopidogrel: the PRINC (Plavix Response in Coronary Intervention) trial. JACC Cardiovasc Interv. 2008;1:612-619.
26. Mega JL, Hochholzer W, Frelinger AL III, Kluk MJ, Angiolillo DJ, Kereiakes DJ, et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA. 2011;306:2221-2228.
27. Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, et al Clinical Pharmacogenetics Implementation Consortium. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin Pharmacol Ther. 2011;90:328-332.
28. Camps J, Joven J, Mackness B, Mackness M, Tawfik D, Draganov D, et al. Paraoxonase-1 and clopidogrel efficacy. Nat Med. 2011;17:1041-1042; author reply 1042.
29. Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302:849-857.
30. Taubert D, von Beckerath N, Grimberg G, Lazar A, Jung N, Goeser T, et al. Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther. 2006;80:486-501.
31. Gerloff T, Schaefer M, Johne A, Oselin K, Meisel C, Cascorbi I, et al. MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br J Clin Pharmacol. 2002;54:610-616.
32. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with Pglycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000;97:3473-3478.
33. Leschziner GD, Andrew T, Pirmohamed M, Johnson MR. ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J. 2007;7:154-179.
34. Nakamura T, Sakaeda T, Horinouchi M, Tamura T, Aoyama N, Shirakawa T, et al. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin Pharmacol Ther. 2002;71:297-303.